Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial

Table 1 Formulation of Product

Dose Groups	Peptides loaded / HLA class	Peptide loading method and concentration	DEX dose (expressed as numbers of MHC class II molecules)
A	MAGE A3 (168–176) / class I	Indirect (10 μg/mL)	0.13 × 10¹⁴
	MAGE A3 (247–258) / class II	Indirect (10 μg/mL)
	tetanus toxoid / class II	Indirect (10 μg/mL)
B	MAGE A3 (168–176) / class I	Indirect (10 μg/mL)	0.4 × 10¹⁴
	MAGE A3 (247–258) / class II	Indirect (10 μg/mL)
C	MAGE A3 (168–176) / class I	Direct (10 μg/mL)	0.13 × 10¹⁴
	MAGE A3 (247–258) / class II	Indirect (10 μg/mL)
	tetanus toxoid / class II	Indirect (10 μg/mL)
D	MAGE A3 (168–176) / class I	Direct (100 μg/mL)	0.13 × 10¹⁴
	MAGE A3 (247–258) / class II	Indirect (10 μg/mL)

ISSN: 1479-5876